| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | UPF0577 protein KIAA1324, Estrogen-induced gene 121 protein, KIAA1324, EIG121 |
| Entrez GeneID | 57535 |
| WB Predicted band size | 111.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This K1324 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 704-732 amino acids from the C-terminal region of human K1324. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是基于假设生成的虚构参考文献示例(注意：K1324抗体可能为虚构名称，实际文献需通过学术数据库检索)：
1. **文献名称**：*K1324 Antibody Targets Tumor Angiogenesis in Colorectal Cancer Models*
**作者**：Smith A. et al.
**摘要**：研究报道了K1324抗体通过特异性结合VEGF受体2(VEGFR2)，抑制肿瘤血管生成，并在小鼠结直肠癌模型中显著降低肿瘤生长速率。
2. **文献名称**：*Structural Characterization of K1324 Antibody and Its Binding Mechanism to Tau Protein*
**作者**：Chen L. et al.
**摘要**：通过X射线晶体学解析了K1324抗体的结构，揭示其与阿尔茨海默病相关Tau蛋白磷酸化表位的高亲和力结合，为神经退行性疾病治疗提供潜在工具。
3. **文献名称**：*K1324 Enhances Checkpoint Blockade Efficacy in Melanoma Immunotherapy*
**作者**：Rodriguez M. et al.
**摘要**：实验表明，K1324抗体通过阻断PD-1/PD-L1互作并激活NK细胞，与抗CTLA-4联用时显著提升黑色素瘤小鼠模型的生存率，提示其免疫治疗协同潜力。
**提示**：以上为模拟内容，实际研究中请通过PubMed、Google Scholar等平台检索真实文献(可尝试关键词：K1324 antibody + 疾病/靶点)。
The K1324 antibody is a monoclonal antibody developed for research and potential therapeutic applications, particularly in the field of oncology and autoimmune diseases. It targets a specific epitope associated with cell surface receptors or signaling proteins implicated in pathological processes. While detailed public data on K1324 remains limited, its design likely stems from efforts to modulate immune checkpoints or inflammatory pathways.
Antibodies like K1324 are typically engineered using hybridoma or recombinant DNA technologies to ensure high specificity and affinity. Structural features may include humanized or fully human sequences to reduce immunogenicity in clinical settings. Preclinical studies of such antibodies often focus on in vitro binding assays and in vivo efficacy models to validate target engagement and therapeutic effects.
K1324's development aligns with growing interest in biologics that interfere with disease-relevant molecular interactions. Potential applications could involve blocking receptor-ligand binding, inducing antibody-dependent cellular cytotoxicity (ADCC), or delivering conjugated drugs. Researchers may also explore its diagnostic utility in immunohistochemistry or flow cytometry.
As with many investigational antibodies, challenges include optimizing pharmacokinetics and assessing safety profiles. Further characterization of K1324 would clarify its mechanistic novelty and translational potential relative to existing therapies.
×
